Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. lowered its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 7.9% during the third quarter, HoldingsChannel.com reports. The fund owned 215,818 shares of the biotechnology company’s stock after selling 18,404 shares during the quarter. Arrowhead Pharmaceuticals accounts for approximately 2.7% of Privium Fund Management B.V.’s holdings, making the stock its 12th largest holding. Privium Fund Management B.V.’s holdings in Arrowhead Pharmaceuticals were worth $14,125,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the last quarter. Carolina Wealth Advisors LLC grew its holdings in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Optiver Holding B.V. grew its holdings in Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at $39,000. Finally, Allied Private Wealth LLC purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at $43,000. 62.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ARWR has been the subject of several research reports. Piper Sandler reaffirmed an “overweight” rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 17th. The Goldman Sachs Group started coverage on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 24th. They set a “neutral” rating and a $74.00 target price for the company. JPMorgan Chase & Co. raised their target price on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, UBS Group started coverage on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. They set a “buy” rating and a $109.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.07.

Insiders Place Their Bets

In related news, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares in the company, valued at approximately $2,747,936. This trade represents a 5.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock traded up $0.70 during mid-day trading on Friday, hitting $58.16. 1,363,195 shares of the company were exchanged, compared to its average volume of 1,708,830. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The business’s 50 day simple moving average is $66.91 and its two-hundred day simple moving average is $71.48. The company has a market capitalization of $8.19 billion, a P/E ratio of -25.85 and a beta of 1.34. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $37.06 and a 12-month high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%. The company had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. During the same period last year, the firm earned ($1.26) earnings per share. The business’s revenue was up 171.0% compared to the same quarter last year. Analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.62 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.